Arvinas Overview
Latest P/E ratio for Arvinas: 39.95 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow39.95
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for ARVN is 39.95. That is above the Healthcare sector average of 25.3. Investors often review this figure alongside Arvinas's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ARVN currently prints 39.95 for P/E ratio, while the sector average sits near 25.3. That is roughly 57.9% above the sector mean. Large gaps often invite a closer look at Arvinas's growth, margins, and balance sheet.
A P/E ratio of 39.95 for Arvinas is not 'good' or 'bad' on its own. Compare it with the peer average (25.3) and with ARVN's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting ARVN's P/E ratio (39.95), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Arvinas's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
